X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $930.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 22, 2022
Details:
Through the transaction, Alcon has added the commercial products Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% and Rhopressa (netarsudil ophthalmic solution) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 22, 2022
Details:
Alcon will add Rocklatan (netarsudil and latanoprost ophthalmic solution) and Rhopressa (netarsudil ophthalmic solution), as well as AR-15512, a Phase 3 candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical candidates.
Lead Product(s): Netarsudil,Latanoprost
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Alcon Inc
Deal Size: $930.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition August 22, 2022
Details:
Rocklatan (netarsudil and latanoprost), indicated for reduction of elevated IOP in patients with glaucoma or ocular hypertension, demonstrated consistent IOP reduction of ~9.5 mmHg and an average IOP reduction of 37% from baseline in European Phase 3B clinical trial.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Product Name: Rocklatan
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Santen will be responsible for all development and commercialization costs and activities related to the products in the territories covered by the agreement with the exception of a post-marketing clinical study to be conducted by Aerie in Europe for Rhopressa and Rocklatan.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Product Name: Rhopressa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Santen Pharmaceutical
Deal Size: $168.0 million Upfront Cash: $88.0 million
Deal Type: Expanded Collaboration December 07, 2021
Details:
THC-VHS-NEC (SBI-100) + Rhopressa® (netarsudil) a Rho-Kinase Inhibitor combination , Produces Superior IOP Lowering Activity.THCVHS a synthetic molecule, developed to treat glaucoma.
Lead Product(s): 9-delta-Tetrahydrocannabinol-valine-hemisuccinate,Netarsudil
Therapeutic Area: Ophthalmology Product Name: THC-VHS
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2021
Details:
Santen will look after sales, marketing and pricing decisions relating to Rhopressa® and Rocklatan®. Aerie and Santen will collaborate for the first Phase 3 study for Rhopressa® in Japan.
Lead Product(s): Netarsudil
Therapeutic Area: Ophthalmology Product Name: Rhopressa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Santen Pharmaceutical
Deal Size: $149.0 million Upfront Cash: $50.0 million
Deal Type: Licensing Agreement October 28, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
